What is Sofosbuvir + Velpatasvir?

Sofosbuvir + Velpatasvir is an orally active, pan-genotypic direct-acting antiviral (DAA) fixed-dose combination used to treat chronic Hepatitis C virus (HCV) infection. It combines two targeted antivirals—sofosbuvir and velpatasvir—designed to directly inhibit essential viral proteins required for Hepatitis C replication. By stopping the virus from multiplying, this therapy allows the liver to clear the infection and begin healing.

Unlike older treatments that relied on interferon injections with harsh systemic side effects, Sofosbuvir + Velpatasvir offers an all-oral, once-daily regimen. It is prescribed after clinical and laboratory evaluations confirm the patient's viral strain, liver status, and overall health.

What is Sofosbuvir + Velpatasvir Used For?

Sofosbuvir + Velpatasvir is indicated for adults and pediatric patients (3 years of age and older) across several specific clinical settings, including:

• All Major HCV Genotypes (Genotypes 1, 2, 3, 4, 5, and 6): Effective across all major Hepatitis C strains without requiring complex prior genotype testing.
• Patients Without Cirrhosis or With Compensated Cirrhosis: Administered as a standalone single-tablet regimen for 12 weeks.
• Decompensated Cirrhosis (Advanced Liver Failure): Used in combination with Ribavirin to manage severe liver impairment.
• HCV Co-infections: Suitable for managing chronic Hepatitis C in patients co-infected with HIV-1.

Treatment selection and duration are always individualized based on liver function, prior treatment history, and clinical guidelines.

How Does Sofosbuvir + Velpatasvir Work?

The Hepatitis C virus relies on specific enzymes and proteins inside host liver cells to copy its genetic material and replicate. Sofosbuvir + Velpatasvir combines two distinct mechanisms of action:

• Sofosbuvir (NS5B Polymerase Inhibitor): Acts as a nucleotide prodrug that incorporates into viral RNA, halting the NS5B RNA-dependent RNA polymerase enzyme and prematurely terminating viral replication chains.
• Velpatasvir (NS5A Protein Inhibitor): Targets and inhibits the HCV NS5A protein, which is essential for viral RNA replication and viral assembly.
• Viral Clearance: Rapidly suppresses viral load in the bloodstream, enabling sustained virologic response (SVR).
• Liver Protection: Halts ongoing liver inflammation, lowering long-term risks of cirrhosis, liver failure, and hepatocellular carcinoma.

Directly targeting the virus rather than altering the host immune system provides high cure rates with fewer systemic side effects.

Benefits of Sofosbuvir + Velpatasvir

Clinical studies have demonstrated major advantages in appropriate patients:

• Pan-Genotypic Coverage: Highly effective against all 6 major HCV genotypes, eliminating genotype-based treatment hurdles.
• High Cure Rates (SVR12): Clinical trials show cure rates exceeding 95–98% after a 12-week regimen.
• Convenient Oral Dosing: Single daily tablet replaces inconvenient multi-drug injection schedules.
• Short Treatment Duration: Most patients complete therapy in just 12 weeks.
• Well-Tolerated: Lacks the severe side effects associated with older pegylated-interferon therapies.
• Restores Quality of Life: Curing Hepatitis C reduces chronic fatigue, improves long-term liver health, and prevents disease transmission.

Note: Individual clinical outcomes depend on baseline liver status and strict adherence.

Who Should Receive Sofosbuvir + Velpatasvir?

Sofosbuvir + Velpatasvir may be appropriate for patients who:

• Have confirmed chronic Hepatitis C virus (HCV) infection (Genotypes 1–6).
• Are treatment-naïve or have failed prior treatment with older regimens (e.g., peg-interferon/ribavirin).
• Range from adults to pediatric patients at least 3 years old (or weighing $\ge 17\text{ kg}$).
• Have undergone medical clearance by a gastroenterologist, hepatologist, or infectious disease specialist.

Important: Patients should never adjust doses or stop treatment early without consulting their specialist.

Available Strengths

Sofosbuvir + Velpatasvir fixed-dose combinations are commonly available as:

• 400 mg / 100 mg Tablets: Standard adult strength containing 400 mg Sofosbuvir and 100 mg Velpatasvir.
• 200 mg / 50 mg Tablets: Lower strength for pediatric patients weighing between 17 kg and 30 kg.
• Oral Pellets (150 mg / 37.5 mg and 200 mg / 50 mg packets): Formulated for young children or patients who cannot swallow solid tablets whole.

The appropriate strength and formulation are determined based on patient age, body weight, and clinical guidelines.

Recommended Dosage

• Adult Dose: One 400 mg / 100 mg tablet taken orally once daily for 12 weeks.
• Decompensated Cirrhosis: One 400 mg / 100 mg tablet once daily + weight-based Ribavirin for 12 weeks.
• Pediatric Dose (3 years and older): Dosed according to body weight brackets ($\ge 30\text{ kg}$, $17\text{ to }